• 1
    Horny HP,Valent P. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25: 543551.
  • 2
    Horny H-P,Metcalfe DD,Bennett JM, et al. Mastocytosis. In: SwerdlowS, HarrisNL, SteinH, JaffeES, TheileJ, VardimanJW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. pp 5463.
  • 3
    Valent P,Horny HP,Escribano L, et al. Diagnostic criteria and classification of mastocytosis: A consenus proposal. Leuk Res 2001; 25: 603625.
  • 4
    Wolff K,Komar M,Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25: 519528.
  • 5
    Valent P,Akin C,Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol 2003; 122: 695717.
  • 6
    Horny HP,Sotlar K,Sperr WR,Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage disease: A histopathological challenge. J Clin Pathol 2004; 57: 604608.
  • 7
    Valent P,Akin C,Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations, and response criteria. Eur J Clin Invest 2007; 37: 435453.
  • 8
    Lim K-H,Pardanani A,Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate, or 2-chlorodeoxyadenosine. Am J Hematol.
  • 9
    O'Brien SG,Guilhot F,Larson RA, et al. Imatinib compared with interferon and low- dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003; 348: 9941004.
  • 10
    Cools J,DeAngelo DJ,Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 12011214.
  • 11
    Demetri GD,von Mehren M,Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors New Engl J Med 2002; 347: 472480.
  • 12
    Pardanani A,Elliott M,Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535536.
  • 13
    Vega-Ruiz A,Cortes JE,Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33: 14811484.
  • 14
    Zermati Y,De Sepulveda P,Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22: 660664.
  • 15
    Akin C,Brockow K,D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686692.
  • 16
    Ma Y,Zeng S,Metcalfe DD, et al. The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 17411744.
  • 17
    Akin C,Fumo G,Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 32223225.
  • 18
    Pardanani A,Ketterling RP,Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 30933096.
  • 19
    Corless CL,Harrell PL,Lacouture M, et al. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn 2006; 8: 604612.
  • 20
    Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 2006; 26: 575592.
  • 21
    Shah NP,Lee FY,Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286291.
  • 22
    Schittenhelm MM,Shiraga S,Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473481.
  • 23
    Growney JD,Clark JJ,Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721724.
  • 24
    Gotlib J,Berubé C,Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 28652870.
  • 25
    Verstovsek S,Tefferi A,Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14: 39063915.
  • 26
    Gotlib J,George TI,Corless C, et al. The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial (Abstract). Blood 2007; 110: 1035a.
  • 27
    Gleixner KV,Mayerhofer M,Aichberger KJ, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Blood 2006; 107: 752759.
  • 28
    Pardanani A,Lim KH,Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood, in press.
  • 29
    Sotlar K,Bache A,Stellmacher F, et al. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: A distinct subtype of systemic mastocytosis associated with a clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 2008; 10: 5866.
  • 30
    Garcia-Montero AC,Jara-Acevedo M,Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 23662372.
  • 31
    Tefferi A,Li CY,Butterfield JH,Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307309.
  • 32
    Kluin-Nelemans HC,Oldhoff JM,van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 42704276.
  • 33
    Pardanani A,Hoffbrand AV,Butterfield JH,Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127131.
  • 34
    Lortholary O,Vargaftig J,Feger F, et al. Efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 33 patients (Abstract). Blood 2004; 104: 190a.
  • 35
    Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998; 138: 489495.
  • 36
    Casassus P,Caillat-Vigneron N,Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: Results of a multicentre phase II trial on 20 patients. Br J Haematol 2002; 119: 10901097.
  • 37
    Hauswirth AW,Simonitsch-Klupp I,Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004; 28: 249257.